Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Current and future disease-modifying therapies in multiple sclerosis.
The role of T cell apoptosis in nervous system autoimmunity.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Pages